MY189425A - Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use - Google Patents
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of useInfo
- Publication number
- MY189425A MY189425A MYPI2018702306A MYPI2018702306A MY189425A MY 189425 A MY189425 A MY 189425A MY PI2018702306 A MYPI2018702306 A MY PI2018702306A MY PI2018702306 A MYPI2018702306 A MY PI2018702306A MY 189425 A MY189425 A MY 189425A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- myostatin antibodies
- regions
- polypeptides containing
- nucleic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015247070 | 2015-12-18 | ||
PCT/JP2016/087487 WO2017104783A1 (en) | 2015-12-18 | 2016-12-16 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MY189425A true MY189425A (en) | 2022-02-10 |
Family
ID=59011957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2018702306A MY189425A (en) | 2015-12-18 | 2016-12-16 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3390443A4 (en) |
JP (4) | JP6142069B1 (en) |
KR (3) | KR20230027321A (en) |
CN (2) | CN108473562B (en) |
AR (1) | AR107078A1 (en) |
AU (1) | AU2016372934B2 (en) |
BR (1) | BR112018011073A2 (en) |
CA (1) | CA3002422A1 (en) |
EA (1) | EA201891420A1 (en) |
HK (1) | HK1254755A1 (en) |
MX (1) | MX2018007145A (en) |
MY (1) | MY189425A (en) |
PH (1) | PH12018501280A1 (en) |
SG (2) | SG10201707267RA (en) |
TW (3) | TWI605057B (en) |
WO (1) | WO2017104783A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104761637B (en) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | Method for regulating antibody hemodynamics |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
TWI564021B (en) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
TWI761912B (en) | 2010-11-30 | 2022-04-21 | 日商中外製藥股份有限公司 | Antibody having calcium-dependent antigen-binding ability |
EP3795215A1 (en) | 2012-05-30 | 2021-03-24 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
WO2014030750A1 (en) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | MOUSE FcγRII-SPECIFIC Fc ANTIBODY |
CN113831406A (en) | 2012-08-24 | 2021-12-24 | 中外制药株式会社 | Fc gamma RIIb specific Fc region variants |
CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
MX2016007312A (en) | 2013-12-04 | 2017-01-13 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules. |
PE20171111A1 (en) | 2014-12-19 | 2017-08-07 | Chugai Pharmaceutical Co Ltd | ANTIMIOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT HR REGIONS, AND METHODS OF USE |
EA201791754A1 (en) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | ANTIBODIES CONTAINING ANTIGEN-BINDING DOMAIN DEPENDING ON THE CONCENTRATION OF IONS, Fc-AREA OPTIONS, IL-8-CONNECTING ANTIBODIES AND THEIR APPLICATIONS |
AU2016372934B2 (en) * | 2015-12-18 | 2023-10-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
TW202228778A (en) * | 2016-06-17 | 2022-08-01 | 日商中外製藥股份有限公司 | Anti-myostatin antibodies and methods of use |
WO2018025982A1 (en) | 2016-08-05 | 2018-02-08 | 中外製薬株式会社 | Composition for prophylaxis or treatment of il-8 related diseases |
CN110352074A (en) | 2017-02-28 | 2019-10-18 | 西雅图遗传学公司 | Cysteine mutation antibody for coupling |
EA202190451A1 (en) | 2018-08-10 | 2021-07-13 | Чугаи Сейяку Кабусики Кайся | ANTI-CD137 ANTIGEN-BINDING MOLECULES AND THEIR APPLICATION |
KR20210149779A (en) | 2019-04-10 | 2021-12-09 | 추가이 세이야쿠 가부시키가이샤 | Purification method of Fc region modified antibody |
RU2750267C1 (en) * | 2020-02-07 | 2021-06-25 | Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» | Recombinant growth differentiation factor 11 (gdf11), a method for its production, an injectable drug for increasing the muscle mass of mammals and poultry as well as a method of using the drug |
TW202144395A (en) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | Anti-CD137 antigen-binding molecule for use in cancer treatment |
WO2023057404A1 (en) | 2021-10-06 | 2023-04-13 | F. Hoffmann-La Roche Ag | Novel combined administration |
WO2023187022A1 (en) | 2022-04-01 | 2023-10-05 | F. Hoffmann-La Roche Ag | New treatment for facioscapulohumeral muscular dystrophy (fshd) |
KR20230156844A (en) | 2022-05-02 | 2023-11-14 | 노보 노르디스크 에이/에스 | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutabeous administration |
CN116990528B (en) * | 2023-09-27 | 2024-02-06 | 成都华西海圻医药科技有限公司 | Analysis method for rapidly determining anti-CD40 monoclonal antibody based on Gyrolab platform |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
WO2006036834A2 (en) * | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
JP5058261B2 (en) * | 2006-09-05 | 2012-10-24 | イーライ リリー アンド カンパニー | Anti-myostatin antibody |
PE20091163A1 (en) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | ANTIBODIES FOR GDF8 |
TWI564021B (en) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
AR074777A1 (en) * | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | PROTEINS OF UNION TO ANTIGEN |
CN102844332B (en) * | 2010-03-11 | 2015-08-19 | 瑞纳神经科学公司 | The antibody combined in pH dependence antigen |
TW201210612A (en) * | 2010-06-03 | 2012-03-16 | Glaxo Group Ltd | Humanised antigen binding proteins |
MY172730A (en) * | 2012-03-16 | 2019-12-11 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
TWI619729B (en) * | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | Anti-hla-b*27 antibodies and uses thereof |
AR092098A1 (en) * | 2012-08-13 | 2015-03-25 | Regeneron Pharma | ANTI-PCSK9 ANTIBODIES WITH PHASE DEPENDENT UNION CHARACTERISTICS |
CN113831406A (en) * | 2012-08-24 | 2021-12-24 | 中外制药株式会社 | Fc gamma RIIb specific Fc region variants |
CA2911514A1 (en) * | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
SG10201801063TA (en) * | 2013-08-14 | 2018-04-27 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
US10307480B2 (en) * | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
WO2016073906A2 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related immunoassays |
PE20171111A1 (en) * | 2014-12-19 | 2017-08-07 | Chugai Pharmaceutical Co Ltd | ANTIMIOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT HR REGIONS, AND METHODS OF USE |
AU2016372934B2 (en) | 2015-12-18 | 2023-10-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
-
2016
- 2016-12-16 AU AU2016372934A patent/AU2016372934B2/en active Active
- 2016-12-16 KR KR1020237005092A patent/KR20230027321A/en not_active Application Discontinuation
- 2016-12-16 MX MX2018007145A patent/MX2018007145A/en unknown
- 2016-12-16 TW TW105141729A patent/TWI605057B/en active
- 2016-12-16 AR ARP160103887A patent/AR107078A1/en unknown
- 2016-12-16 CN CN201680072782.7A patent/CN108473562B/en active Active
- 2016-12-16 TW TW106129765A patent/TWI749057B/en active
- 2016-12-16 KR KR1020177003241A patent/KR101820637B1/en active IP Right Grant
- 2016-12-16 MY MYPI2018702306A patent/MY189425A/en unknown
- 2016-12-16 TW TW110149330A patent/TW202231662A/en unknown
- 2016-12-16 EA EA201891420A patent/EA201891420A1/en unknown
- 2016-12-16 WO PCT/JP2016/087487 patent/WO2017104783A1/en active Application Filing
- 2016-12-16 EP EP16875757.3A patent/EP3390443A4/en active Pending
- 2016-12-16 BR BR112018011073A patent/BR112018011073A2/en active Search and Examination
- 2016-12-16 SG SG10201707267RA patent/SG10201707267RA/en unknown
- 2016-12-16 CA CA3002422A patent/CA3002422A1/en active Granted
- 2016-12-16 SG SG11201610812WA patent/SG11201610812WA/en unknown
- 2016-12-16 CN CN202210678733.5A patent/CN115028721A/en active Pending
- 2016-12-16 JP JP2016244254A patent/JP6142069B1/en active Active
- 2016-12-16 KR KR1020187001235A patent/KR102501335B1/en active IP Right Grant
-
2017
- 2017-05-08 JP JP2017092151A patent/JP7053164B2/en active Active
-
2018
- 2018-06-14 PH PH12018501280A patent/PH12018501280A1/en unknown
- 2018-10-29 HK HK18113798.7A patent/HK1254755A1/en unknown
-
2022
- 2022-03-31 JP JP2022058710A patent/JP2022097485A/en active Pending
-
2023
- 2023-11-29 JP JP2023201204A patent/JP2024023427A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
MX2023001834A (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use. | |
PH12018502213A1 (en) | Anti-myostatin antibodies and methods of use | |
MX2022001222A (en) | Anti-tim-3 antibodies and methods of use thereof. | |
SG10201909716RA (en) | Modified j-chain | |
MX2017014397A (en) | Anti-fcrn antibodies. | |
SG10201909180SA (en) | Humanized anti-c1s antibodies and methods of use thereof | |
PH12016501689A1 (en) | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof | |
MX2019013124A (en) | Uti fusion proteins. | |
PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
MX2015012281A (en) | Improved tnf binding proteins. | |
MX2018003445A (en) | Expression of fc-containing proteins. |